Statin use and risk of prostate cancer and high-grade prostate cancer: Results from the REDUCE study

Prostate Cancer and Prostatic Diseases

Volumn 16, Issue 3, 2013, Pages 254-259

  Freedland, S J ^a,b,c   Hamilton, R J ^d   Gerber, L ^a,b   Banez, L L ^a   Moreira, D M ^a,b   Andriole, G L ^e   Rittmaster, R S ^f  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF TORONTO   (Canada)

^e WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f Hamner Institutes for Health Sciences   (United States)

Author keywords

cholesterol; dutasteride; prostatic neoplasm; statin

Indexed keywords

ANDROSTANOLONE; DUTASTERIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGE; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY MASS; CANCER GRADING; CANCER RISK; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SIZE; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECONDARY ANALYSIS; SMOKING HABIT; TESTOSTERONE BLOOD LEVEL; TUMOR VOLUME;

AZASTEROIDS; BIOPSY; DOUBLE-BLIND METHOD; EARLY DETECTION OF CANCER; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; KALLIKREINS; LOGISTIC MODELS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK; UNITED STATES;

EID: 84882450774     PISSN: 13657852     EISSN: 14765608     Source Type: Journal    
DOI: 10.1038/pcan.2013.10     Document Type: Article

References (31)

1. Hamilton RJ, Freedland SJ. Rationale for statins in the chemoprevention of prostate cancer. Curr Urol Rep 2008; 9: 189-196.
2. Crawford ED, Black L, Eaddy M, Kruep EJ. A retrospective analysis illustrating the substantial clinical and economic burden of prostate cancer. Prostate Cancer Prostatic Dis 2010; 13: 162-167.
3. Stokes ME, Black L, Benedict A, Roehrborn CG, Albertsen P. Long-term medicalcare costs related to prostate cancer: estimates from linked SEER-Medicare data. Prostate Cancer Prostatic Dis 2010; 13: 278-284.
4. Platz EA, Leitzmann MF, Visvanathan K, Rimm EB, Stampfer MJ, Willett WC et al. Statin drugs and risk of advanced prostate cancer. J Natl Cancer Inst 2006; 98: 1819-1825.
5. Flick ED, Habel LA, Chan KA, Van Den Eeden SK, Quinn VP, Haque R et al. Statin use and risk of prostate cancer in the California Men's health study cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2218-2225.
6. Jacobs EJ, Rodriguez C, Bain EB, Wang Y, Thun MJ, Calle EE. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large US cohort. Cancer Epidemiol Biomarkers Prev 2007; 16: 2213-2217.
7. Murtola TJ, Tammela TL, Lahtela J, Auvinen A. Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev 2007; 16: 2226-2232.
8. Murtola TJ, Tammela TL, Maattanen L, Huhtala H, Platz EA, Ala-Opas M et al. Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer 2010; 127: 1650-1659.
9. Breau RH, Karnes RJ, Jacobson DJ, McGree ME, Jacobsen SJ, Nehra A et al. The association between statin use and the diagnosis of prostate cancer in a population based cohort. J Urol 2010; 184: 494-499.
10. Farwell WR, D'Avolio LW, Scranton RE, Lawler EV, Gaziano JM. Statins and prostate cancer diagnosis and grade in a veterans population. J Natl Cancer Inst 2011; 103: 885-892.
11. Tan N, Klein EA, Li J, Moussa AS, Jones JS. Statin use and risk of prostate cancer in a population of men who underwent biopsy. J Urol 2011; 186: 86-90.
12. Hamilton RJ, Goldberg KC, Platz EA, Freedland SJ. The influence of statin medications on prostate-specific antigen levels. J Natl Cancer Inst 2008; 100: 1511-1518.
13. Mondul AM, Selvin E, De Marzo AM, Freedland SJ, Platz EA. Statin drugs, serum cholesterol, and prostate-specific antigen in the National Health and Nutrition Examination Survey 2001-2004. Cancer Causes Control 2010; 21: 671-678.
14. Chang SL, Harshman LC, Presti Jr. JC. Impact of common medications on serum total prostate-specific antigen levels: analysis of the National Health and Nutrition Examination Survey. J Clin Oncol 2010; 28: 3951-3957.
15. Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-1202.
16. Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F et al. The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol 2011; 185: 126-131.
17. Thomas 2nd JA, Gerber L, Moreira DM, Hamilton RJ, Banez LL, Castro-Santamaria R et al. Prostate cancer risk in men with prostate and breast cancer family history: results from the REDUCE study. J Intern Med 2012; 272: 85-92.
18. Agalliu I, Salinas CA, Hansten PD, Ostrander EA, Stanford JL. Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol 2008; 168: 250-260.
19. Mostaghel EA, Solomon KR, Pelton K, Freeman MR, Montgomery RB. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors. PloS One 2012; 7: e30062.
20. Friis S, Poulsen AH, Johnsen SP, McLaughlin JK, Fryzek JP, Dalton SO et al. Cancer risk among statin users: a population-based cohort study. Int J Cancer 2005; 114: 643-647.
21. Blais L, Desgagne A, LeLorier J. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors and the risk of cancer: a nested case-control study. Arch Intern Med 2000; 160: 2363-2368.
22. Coogan PF, Rosenberg L, Strom BL. Statin use and the risk of 10 cancers. Epidemiology 2007; 18: 213-219.
23. Kaye JA, Jick H. Statin use and cancer risk in the general practice research database. Br J Cancer 2004; 90: 635-637.
24. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366: 1267-1278.
25. Dale KM, Coleman CI, Henyan NN, Kluger J, White CM. Statins and cancer risk: a meta-analysis. JAMA 2006; 295: 74-80.
26. Browning DR, Martin RM. Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer 2007; 120: 833-843.
27. Hamilton RJ, Banez LL, Aronson WJ, Terris MK, Platz EA, Kane CJ et al. Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Cancer 2010; 116: 3389-3398.
28. Hall SA, Page ST, Travison TG, Montgomery RB, Link CL, McKinlay JB. Do statins affect androgen levels in men? Results from the Boston area community health survey. Cancer Epidemiol Biomarkers Prev 2007; 16: 1587-1594.
29. Mondul AM, Selvin E, Rohrmann S, Menke A, Feinleib M, Kanarek N et al. Association of serum cholesterol and cholesterol-lowering drug use with serum sex steroid hormones in men in NHANES III. Cancer Causes Control 2010; 21: 1575-1583.
30. Gutt R, Tonlaar N, Kunnavakkam R, Karrison T, Weichselbaum RR, Liauw SL. Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. J Clin Oncol 2010; 28: 2653-2659.
31. Ku JH, Jeong CW, Park YH, Cho MC, Kwak C, Kim HH. Relationship of statins to clinical presentation and biochemical outcomes after radical prostatectomy in Korean patients. Prostate Cancer Prostatic Dis 2011; 14: 63-68.